New Publication in Journal of Orthopedic Case Reports

Impaired Bone Healing and Fracture Complications during Limb Lengthening in a Patient with Neurofibromatosis Type 1 Receiving Selumetinib: A Case Report and Literature Review

In this case report, we describe a pediatric patient with Neurofibromatosis Type 1 (NF1) who developed impaired bone healing and fracture complications while receiving selumetinib, in the setting of mechanical stress related to limb lengthening.

💡 Learning point:
Selumetinib therapy in pediatric patients with NF1 may be associated with impaired bone healing and an increased risk of pathological fractures, particularly during limb lengthening.

🔍 Conclusion:
In pediatric NF1 patients treated with selumetinib, fractures and impaired bone healing may represent rare but clinically relevant complications, especially in the context of orthopedic procedures. These findings highlight the importance of close monitoring of bone health and a multidisciplinary approach when MEK inhibitor therapy is combined with limb lengthening or other orthopedic interventions.

👉 Read the full article here

Authors: Zahra Safari, Maria Tirta, Ole Rahbek, Søren Kold